Researchers developing the gene expression-based test say it could bring objectivity to a subjective diagnosis and result in more targeted treatments.
The Tulsa, Oklahoma-based lab, which received its CLIA license in August, will run samples reimbursed by Medicare and state Medicaid agencies only.
The designation will help the company accelerate the process of bringing the opioid addiction risk test through regulatory review and clearance.
The guidelines are the first to attempt to specify which drugs are appropriate to test for routinely, guideline authors say.
Qualitative testing offers more specificity and sensitivity than current frontline immunoassay-based testing, the group said in its guidelines.